New Drug Shows Promise for Spinal Cord Injury Recovery
A new experimental drug might help patients with spinal cord injuries regain their mobility. The medication, called NVG-291, has been tested in a phase 2 trial, where some participants experienced significant improvements.
Larry Williams, a 58-year-old from Philadelphia, shared his inspiring story. After suffering paralysis from a mountain-biking accident, Williams has begun to walk again. He was biking when he collided with a tree, resulting in severe injuries to his neck vertebrae. Following spinal surgery, he faced a tough recovery, but with therapy, he gradually started to regain movement.
Before discovering the NVG-291 trial, Williams could only walk a bit with the help of a walker and struggled with mobility in his hands. Over the course of three months, starting in April 2024, he received daily injections of the drug along with physical therapy focused on improving his mobility.
At the trial’s conclusion, he was thrilled to find he could walk ten meters (about 33 feet) in just 15 seconds, a significant improvement from the 45 seconds it had taken before the trial. Remarkably, even after stopping the injections in July 2024, Williams continues to see progress.
“I recently stood up and balanced on one foot for 30 seconds,” he said excitedly, recalling how he couldn’t hold that position for even three seconds six months before. His determination shines through as he approaches daily activities with newfound capability, including swimming laps.
Williams expressed gratitude for the treatment and hopes it opens doors for others with similar injuries. “It seems like I’ve been given a shortcut,” he explained, wishing for full independence once more.
Understanding NVG-291
Dr. Monica Perez, a leading researcher at a rehabilitation center in Chicago, explained how NVG-291 works. Initially tested on animals, it showed promise in restoring movement. The drug functions by blocking signals that prevent nerve fibers from regenerating, allowing them a better chance to heal.
While existing treatments often involve cell therapies, this drug is easy to administer and has shown strong results in clinical trials. Dr. Perez emphasized that further research is needed to understand how long the drug’s effects will last.
Though still not FDA-approved, the team is committed to advancing this treatment. Williams believes in its potential and hopes it can transform lives. “I’m just praying that everyone out there gets a chance to reclaim their life,” he stated, reflecting his deep hope for those suffering from similar injuries.
